APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antitumor Peptide Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antitumor Peptide Drugs Industry Growth and Trends Forecast to 2032

Report ID 173966710123 December 202598 pages

Choose your research edition.

Industry ResearchAntitumor Peptide Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Antitumor Peptide Drugs Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Antitumor Peptide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antitumor Peptide Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Antitumor Peptide Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Antitumor Peptide Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antitumor Peptide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antitumor Peptide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antitumor Peptide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antitumor Peptide Drugs include Ipsen, Novartis, Ferring Pharmaceuticals, AbbVie, AstraZeneca, Tolmar and Foresee Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antitumor Peptide Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antitumor Peptide Drugs market size, estimates, and forecasts are presented in terms of sales volume (kg) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antitumor Peptide Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antitumor Peptide Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antitumor Peptide Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antitumor Peptide Drugs Market by Company

Ipsen

Novartis

Ferring Pharmaceuticals

AbbVie

AstraZeneca

Tolmar

Foresee Pharmaceuticals

Antitumor Peptide Drugs Segment by Type

Leuprolide

Lanreotide

Goserelin

Degarelix

Octreotide

Antitumor Peptide Drugs Segment by Application

Hospital

Clinic

Others

Antitumor Peptide Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antitumor Peptide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antitumor Peptide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antitumor Peptide Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antitumor Peptide Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antitumor Peptide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Leuprolide Table 2. Major Company of Lanreotide Table 3. Major Company of Goserelin Table 4. Major Company of Degarelix Table 5. Major Company of Octreotide Table 6. Global Antitumor Peptide Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Antitumor Peptide Drugs Sales by Type (2021-2026) & (kg) Table 8. Global Antitumor Peptide Drugs Sales Market Share in Volume by Type (2021-2026) Table 9. Global Antitumor Peptide Drugs Sales by Type (2021-2026) & (US$ Million) Table 10. Global Antitumor Peptide Drugs Sales Market Share in Value by Type (2021-2026) Table 11. Global Antitumor Peptide Drugs Price by Type (2021-2026) & (USD/g) Table 12. Global Antitumor Peptide Drugs Sales by Type (2027-2032) & (kg) Table 13. Global Antitumor Peptide Drugs Sales Market Share in Volume by Type (2027-2032) Table 14. Global Antitumor Peptide Drugs Sales by Type (2027-2032) & (US$ Million) Table 15. Global Antitumor Peptide Drugs Sales Market Share in Value by Type (2027-2032) Table 16. Global Antitumor Peptide Drugs Price by Type (2027-2032) & (USD/g) Table 17. North America Antitumor Peptide Drugs Sales by Type (2021-2026) & (kg) Table 18. North America Antitumor Peptide Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Antitumor Peptide Drugs Sales by Type (2021-2026) & (kg) Table 20. Europe Antitumor Peptide Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Antitumor Peptide Drugs Sales by Type (2021-2026) & (kg) Table 22. Asia-Pacific Antitumor Peptide Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Antitumor Peptide Drugs Sales by Type (2021-2026) & (kg) Table 24. Latin America Antitumor Peptide Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Antitumor Peptide Drugs Sales by Type (2021-2026) & (kg) Table 26. Middle East and Africa Antitumor Peptide Drugs Sales by Type (2021-2026) & (US$ Million) Table 27. Antitumor Peptide Drugs Industry Trends Table 28. Antitumor Peptide Drugs Industry Drivers Table 29. Antitumor Peptide Drugs Industry Opportunities and Challenges Table 30. Antitumor Peptide Drugs Industry Restraints Table 31. Global Antitumor Peptide Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Antitumor Peptide Drugs Revenue Market Share by Company (2021-2026) Table 33. Global Antitumor Peptide Drugs Sales by Company (2021-2026) & (kg) Table 34. Global Antitumor Peptide Drugs Sales Share by Company (2021-2026) Table 35. Global Antitumor Peptide Drugs Market Price by Company (2021-2026) & (USD/g) Table 36. Global Antitumor Peptide Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Antitumor Peptide Drugs Major Company Production Sites and Headquarters Table 38. Global Antitumor Peptide Drugs Company, Product Type & Application Table 39. Global Antitumor Peptide Drugs Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Antitumor Peptide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Antitumor Peptide Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Antitumor Peptide Drugs Sales by Region (2021-2026) & (kg) Table 44. Global Antitumor Peptide Drugs Sales Market Share in Volume by Region (2021-2026) Table 45. Global Antitumor Peptide Drugs Sales by Region (2021-2026) & (US$ Million) Table 46. Global Antitumor Peptide Drugs Sales Market Share in Value by Region (2021-2026) Table 47. Global Antitumor Peptide Drugs Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 48. Global Antitumor Peptide Drugs Sales by Region (2027-2032) & (kg) Table 49. Global Antitumor Peptide Drugs Sales Market Share in Volume by Region (2027-2032) Table 50. Global Antitumor Peptide Drugs Sales by Region (2027-2032) & (US$ Million) Table 51. Global Antitumor Peptide Drugs Sales Market Share in Value by Region (2027-2032) Table 52. Global Antitumor Peptide Drugs Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2027-2032) Table 53. Global Antitumor Peptide Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Antitumor Peptide Drugs Sales by Application (2021-2026) & (kg) Table 55. Global Antitumor Peptide Drugs Sales Market Share in Volume by Application (2021-2026) Table 56. Global Antitumor Peptide Drugs Sales by Application (2021-2026) & (US$ Million) Table 57. Global Antitumor Peptide Drugs Sales Market Share in Value by Application (2021-2026) Table 58. Global Antitumor Peptide Drugs Price by Application (2021-2026) & (USD/g) Table 59. Global Antitumor Peptide Drugs Sales by Application (2027-2032) & (kg) Table 60. Global Antitumor Peptide Drugs Sales Market Share in Volume by Application (2027-2032) Table 61. Global Antitumor Peptide Drugs Sales by Application (2027-2032) & (US$ Million) Table 62. Global Antitumor Peptide Drugs Sales Market Share in Value by Application (2027-2032) Table 63. Global Antitumor Peptide Drugs Price by Application (2027-2032) & (USD/g) Table 64. North America Antitumor Peptide Drugs Sales by Application (2021-2026) & (kg) Table 65. North America Antitumor Peptide Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Antitumor Peptide Drugs Sales by Application (2021-2026) & (kg) Table 67. Europe Antitumor Peptide Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Antitumor Peptide Drugs Sales by Application (2021-2026) & (kg) Table 69. Asia-Pacific Antitumor Peptide Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Antitumor Peptide Drugs Sales by Application (2021-2026) & (kg) Table 71. Latin America Antitumor Peptide Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Antitumor Peptide Drugs Sales by Application (2021-2026) & (kg) Table 73. Middle East and Africa Antitumor Peptide Drugs Sales by Application (2021-2026) & (US$ Million) Table 74. Ipsen Company Information Table 75. Ipsen Business Overview Table 76. Ipsen Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 77. Ipsen Antitumor Peptide Drugs Product Portfolio Table 78. Ipsen Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 82. Novartis Antitumor Peptide Drugs Product Portfolio Table 83. Novartis Recent Development Table 84. Ferring Pharmaceuticals Company Information Table 85. Ferring Pharmaceuticals Business Overview Table 86. Ferring Pharmaceuticals Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 87. Ferring Pharmaceuticals Antitumor Peptide Drugs Product Portfolio Table 88. Ferring Pharmaceuticals Recent Development Table 89. AbbVie Company Information Table 90. AbbVie Business Overview Table 91. AbbVie Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 92. AbbVie Antitumor Peptide Drugs Product Portfolio Table 93. AbbVie Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 97. AstraZeneca Antitumor Peptide Drugs Product Portfolio Table 98. AstraZeneca Recent Development Table 99. Tolmar Company Information Table 100. Tolmar Business Overview Table 101. Tolmar Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 102. Tolmar Antitumor Peptide Drugs Product Portfolio Table 103. Tolmar Recent Development Table 104. Foresee Pharmaceuticals Company Information Table 105. Foresee Pharmaceuticals Business Overview Table 106. Foresee Pharmaceuticals Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 107. Foresee Pharmaceuticals Antitumor Peptide Drugs Product Portfolio Table 108. Foresee Pharmaceuticals Recent Development Table 109. North America Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 110. North America Antitumor Peptide Drugs Sales by Country (2021-2026) & (kg) Table 111. North America Antitumor Peptide Drugs Sales Market Share by Country (2021-2026) Table 112. North America Antitumor Peptide Drugs Sales Forecast by Country (2027-2032) & (kg) Table 113. North America Antitumor Peptide Drugs Sales Market Share Forecast by Country (2027-2032) Table 114. North America Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 115. North America Antitumor Peptide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 116. North America Antitumor Peptide Drugs Market Share by Country (2021-2026) Table 117. North America Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 118. North America Antitumor Peptide Drugs Market Share Forecast by Country (2027-2032) Table 119. Europe Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 120. Europe Antitumor Peptide Drugs Sales by Country (2021-2026) & (kg) Table 121. Europe Antitumor Peptide Drugs Sales Market Share by Country (2021-2026) Table 122. Europe Antitumor Peptide Drugs Sales Forecast by Country (2027-2032) & (kg) Table 123. Europe Antitumor Peptide Drugs Sales Market Share Forecast by Country (2027-2032) Table 124. Europe Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. Europe Antitumor Peptide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 126. Europe Antitumor Peptide Drugs Market Share by Country (2021-2026) Table 127. Europe Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. Europe Antitumor Peptide Drugs Market Share Forecast by Country (2027-2032) Table 129. Asia-Pacific Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 130. Asia-Pacific Antitumor Peptide Drugs Sales by Country (2021-2026) & (kg) Table 131. Asia-Pacific Antitumor Peptide Drugs Sales Market Share by Country (2021-2026) Table 132. Asia-Pacific Antitumor Peptide Drugs Sales Forecast by Country (2027-2032) & (kg) Table 133. Asia-Pacific Antitumor Peptide Drugs Sales Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific Antitumor Peptide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 136. Asia-Pacific Antitumor Peptide Drugs Market Share by Country (2021-2026) Table 137. Asia-Pacific Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Asia-Pacific Antitumor Peptide Drugs Market Share Forecast by Country (2027-2032) Table 139. Latin America Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 140. Latin America Antitumor Peptide Drugs Sales by Country (2021-2026) & (kg) Table 141. Latin America Antitumor Peptide Drugs Sales Market Share by Country (2021-2026) Table 142. Latin America Antitumor Peptide Drugs Sales Forecast by Country (2027-2032) & (kg) Table 143. Latin America Antitumor Peptide Drugs Sales Market Share Forecast by Country (2027-2032) Table 144. Latin America Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Latin America Antitumor Peptide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 146. Latin America Antitumor Peptide Drugs Market Share by Country (2021-2026) Table 147. Latin America Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Latin America Antitumor Peptide Drugs Market Share Forecast by Country (2027-2032) Table 149. Middle East and Africa Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (kg): 2021 VS 2025 VS 2032 Table 150. Middle East and Africa Antitumor Peptide Drugs Sales by Country (2021-2026) & (kg) Table 151. Middle East and Africa Antitumor Peptide Drugs Sales Market Share by Country (2021-2026) Table 152. Middle East and Africa Antitumor Peptide Drugs Sales Forecast by Country (2027-2032) & (kg) Table 153. Middle East and Africa Antitumor Peptide Drugs Sales Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa Antitumor Peptide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Antitumor Peptide Drugs Market Share by Country (2021-2026) Table 157. Middle East and Africa Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Middle East and Africa Antitumor Peptide Drugs Market Share Forecast by Country (2027-2032) Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. Antitumor Peptide Drugs Distributors List Table 162. Antitumor Peptide Drugs Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Antitumor Peptide Drugs Image Figure 2. Global Antitumor Peptide Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antitumor Peptide Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Antitumor Peptide Drugs Sales (2021-2032) & (kg) Figure 5. Leuprolide Image Figure 6. Global Leuprolide Sales YoY Growth (2021-2032) & (kg) Figure 7. Lanreotide Image Figure 8. Global Lanreotide Sales YoY Growth (2021-2032) & (kg) Figure 9. Goserelin Image Figure 10. Global Goserelin Sales YoY Growth (2021-2032) & (kg) Figure 11. Degarelix Image Figure 12. Global Degarelix Sales YoY Growth (2021-2032) & (kg) Figure 13. Octreotide Image Figure 14. Global Octreotide Sales YoY Growth (2021-2032) & (kg) Figure 15. Global Antitumor Peptide Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Antitumor Peptide Drugs Market Share by Type 2025 VS 2032 Figure 17. North America Antitumor Peptide Drugs Sales Market Share in Volume by Type in 2025 Figure 18. North America Antitumor Peptide Drugs Sales Market Share in Value by Type in 2025 Figure 19. Europe Antitumor Peptide Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Europe Antitumor Peptide Drugs Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Antitumor Peptide Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Antitumor Peptide Drugs Sales Market Share in Value by Type in 2025 Figure 23. Latin America Antitumor Peptide Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Antitumor Peptide Drugs Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Antitumor Peptide Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Antitumor Peptide Drugs Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Antitumor Peptide Drugs Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (kg) Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (kg) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (kg) Figure 35. Global Antitumor Peptide Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Antitumor Peptide Drugs Market Share by Application 2025 VS 2032 Figure 37. North America Antitumor Peptide Drugs Sales Market Share in Volume by Application in 2025 Figure 38. North America Antitumor Peptide Drugs Sales Market Share in Value by Application in 2025 Figure 39. Europe Antitumor Peptide Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Europe Antitumor Peptide Drugs Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Antitumor Peptide Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Antitumor Peptide Drugs Sales Market Share in Value by Application in 2025 Figure 43. Latin America Antitumor Peptide Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Antitumor Peptide Drugs Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Antitumor Peptide Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Antitumor Peptide Drugs Sales Market Share in Value by Application in 2025 Figure 47. North America Antitumor Peptide Drugs Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 48. North America Antitumor Peptide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Antitumor Peptide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Antitumor Peptide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Antitumor Peptide Drugs Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 52. Europe Antitumor Peptide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Antitumor Peptide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Antitumor Peptide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Antitumor Peptide Drugs Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 56. Asia-Pacific Antitumor Peptide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Antitumor Peptide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Antitumor Peptide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Antitumor Peptide Drugs Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 60. Latin America Antitumor Peptide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Antitumor Peptide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Antitumor Peptide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Antitumor Peptide Drugs Sales by Country: 2021 VS 2025 VS 2032 (kg) Figure 64. Middle East and Africa Antitumor Peptide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Antitumor Peptide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Antitumor Peptide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Antitumor Peptide Drugs Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Antitumor Peptide Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Leuprolide
  • Lanreotide
  • Goserelin
  • Degarelix
  • Octreotide
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Ipsen
  • Novartis
  • Ferring Pharmaceuticals
  • AbbVie
  • AstraZeneca
  • Tolmar
  • Foresee Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antitumor Peptide Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antitumor Peptide Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antitumor Peptide Drugs Market by Type
  6. 1.3.1 Leuprolide
  7. 1.3.2 Lanreotide
  8. 1.3.3 Goserelin
  9. 1.3.4 Degarelix
  10. 1.3.5 Octreotide
  11. 1.4 Global Antitumor Peptide Drugs Market Size by Type
  12. 1.4.1 Global Antitumor Peptide Drugs Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Antitumor Peptide Drugs Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Antitumor Peptide Drugs Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Antitumor Peptide Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Antitumor Peptide Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Antitumor Peptide Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Antitumor Peptide Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Antitumor Peptide Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antitumor Peptide Drugs Industry Trends
  2. 2.2 Antitumor Peptide Drugs Industry Drivers
  3. 2.3 Antitumor Peptide Drugs Industry Opportunities and Challenges
  4. 2.4 Antitumor Peptide Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antitumor Peptide Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Antitumor Peptide Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Antitumor Peptide Drugs Price (2021-2026)
  4. 3.4 Global Antitumor Peptide Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antitumor Peptide Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Antitumor Peptide Drugs Company, Product Type & Application
  7. 3.7 Global Antitumor Peptide Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antitumor Peptide Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antitumor Peptide Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antitumor Peptide Drugs Tier 1, Tier 2, and Tier 3
4 Antitumor Peptide Drugs Regional Status and Outlook
  1. 4.1 Global Antitumor Peptide Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antitumor Peptide Drugs Historic Market Size by Region
  3. 4.2.1 Global Antitumor Peptide Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antitumor Peptide Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antitumor Peptide Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antitumor Peptide Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Antitumor Peptide Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antitumor Peptide Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antitumor Peptide Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antitumor Peptide Drugs by Application
  1. 5.1 Antitumor Peptide Drugs Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Antitumor Peptide Drugs Market Size by Application
  6. 5.2.1 Global Antitumor Peptide Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Antitumor Peptide Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Antitumor Peptide Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Antitumor Peptide Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Antitumor Peptide Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Antitumor Peptide Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Antitumor Peptide Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Antitumor Peptide Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Ipsen
  2. 6.1.1 Ipsen Company Information
  3. 6.1.2 Ipsen Business Overview
  4. 6.1.3 Ipsen Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Ipsen Antitumor Peptide Drugs Product Portfolio
  6. 6.1.5 Ipsen Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Antitumor Peptide Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Ferring Pharmaceuticals
  14. 6.3.1 Ferring Pharmaceuticals Company Information
  15. 6.3.2 Ferring Pharmaceuticals Business Overview
  16. 6.3.3 Ferring Pharmaceuticals Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Ferring Pharmaceuticals Antitumor Peptide Drugs Product Portfolio
  18. 6.3.5 Ferring Pharmaceuticals Recent Developments
  19. 6.4 AbbVie
  20. 6.4.1 AbbVie Company Information
  21. 6.4.2 AbbVie Business Overview
  22. 6.4.3 AbbVie Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 AbbVie Antitumor Peptide Drugs Product Portfolio
  24. 6.4.5 AbbVie Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Antitumor Peptide Drugs Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Tolmar
  32. 6.6.1 Tolmar Company Information
  33. 6.6.2 Tolmar Business Overview
  34. 6.6.3 Tolmar Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Tolmar Antitumor Peptide Drugs Product Portfolio
  36. 6.6.5 Tolmar Recent Developments
  37. 6.7 Foresee Pharmaceuticals
  38. 6.7.1 Foresee Pharmaceuticals Company Information
  39. 6.7.2 Foresee Pharmaceuticals Business Overview
  40. 6.7.3 Foresee Pharmaceuticals Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Foresee Pharmaceuticals Antitumor Peptide Drugs Product Portfolio
  42. 6.7.5 Foresee Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Antitumor Peptide Drugs Sales by Country
  2. 7.1.1 North America Antitumor Peptide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antitumor Peptide Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Antitumor Peptide Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antitumor Peptide Drugs Market Size by Country
  6. 7.2.1 North America Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antitumor Peptide Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antitumor Peptide Drugs Sales by Country
  2. 8.1.1 Europe Antitumor Peptide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antitumor Peptide Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Antitumor Peptide Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antitumor Peptide Drugs Market Size by Country
  6. 8.2.1 Europe Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antitumor Peptide Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antitumor Peptide Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Antitumor Peptide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antitumor Peptide Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antitumor Peptide Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antitumor Peptide Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antitumor Peptide Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antitumor Peptide Drugs Sales by Country
  2. 10.1.1 South America Antitumor Peptide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antitumor Peptide Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Antitumor Peptide Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antitumor Peptide Drugs Market Size by Country
  6. 10.2.1 South America Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antitumor Peptide Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antitumor Peptide Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Antitumor Peptide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antitumor Peptide Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antitumor Peptide Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antitumor Peptide Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Antitumor Peptide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antitumor Peptide Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antitumor Peptide Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antitumor Peptide Drugs Value Chain Analysis
  2. 12.1.1 Antitumor Peptide Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antitumor Peptide Drugs Production Mode & Process
  7. 12.2 Antitumor Peptide Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antitumor Peptide Drugs Distributors
  10. 12.2.3 Antitumor Peptide Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst